EC Number   |
General Information |
Reference |
|---|
   2.5.1.26 | malfunction |
AGPS protein level and phosphatidylethanolamine plasmalogen level are decreased in amyloid-beta protein precursor-deficient cells and brains, overview |
723024 |
| 2.5.1.26 | malfunction |
AGPS silencing suppresses the proliferation and migration potential of glioma U87MG cells, and suppresses the expression of the circular RNAs circ-ubiquitin-associated protein 2, circ-zinc finger protein 292 and circ-homeodomain-interacting protein kinase 3, and the long non-coding RNAs H19 imprinted maternally expressed transcript (non-protein coding), colon cancer-associated transcript 1 (non-protein coding) and hepatocellular carcinoma upregulated long non-coding RNA |
751764 |
| 2.5.1.26 | malfunction |
cataracts and male infertility in blind sterile 2 (bs2) mice are caused by a spontaneous hypomorphic mutation in gene agp. Infertility in bs2 mice is due to the aberrant formation of multicellular cellular clusters that undergo apoptosis. The majority of Agps knock-out mice die embryonically. Correlations of RCDP3 and bs2 phenotypes, detailed overview |
-, 739078 |
| 2.5.1.26 | malfunction |
effects of AGPS silencing and knockout on circRNA expression in the thyroid cancer cell line FRO are investigated using circRNAs microarray |
759876 |
| 2.5.1.26 | malfunction |
in plasmalogen-deficient Chinese hamster ovary mutant, ZPEG251, alkyl-dihydroxyacetonephosphate synthase, is defective. ADAPS mRNA is barely detectable by Northern blot and RT-PCR analyses. Defect of ADAPS expression is also assessed by immunoblot. Ectopic expression of ADAPS-EGFP, enhances the plasmalogen level |
702411 |
| 2.5.1.26 | malfunction |
knockdown of alkylglycerone-phosphate synthase leads to an overall reduction of ether lipid levels, as well as oncogenic signaling molecules, such as LPAe, PAFe and eicosanoids |
759149 |
| 2.5.1.26 | malfunction |
knockdown of alkylglycerone-phosphate synthase leads to an overall reduction of ether lipid levels, as well as oncogenic signaling molecules, such as LPAe, PAFe and eicosanoids, and it shows lower tumor growth rates in xenograft mice |
759149 |
| 2.5.1.26 | malfunction |
knockdown of enzyme AGPS restores the drug sensitivity in glioma U-87MG/DDP and hepatic carcinoma Hep-G2/ADM cell lines. Silencing of AGPS leads to reduced cellular level of lysophosphatidic acid, lysophosphatidic acid-ether and prostaglandin E2, which can fuel aggressive and progress of cancer. Knockdown of AGPS also results in downregulation of multi-drug resistance proteins and anti-apoptosis proteins |
737578 |
| 2.5.1.26 | malfunction |
mutations in alkylglycerone phosphate synthase cause rhizomelic chondrodysplasia punctata, RCDP type 3 (RCDP3), a genetically heterogeneous autosomal recessive syndrome characterized by congenital cataracts, shortening of the proximal limbs, neurological abnormalities, seizures, growth delays, and severe intellectual disability. RCDP children die in the first decade of life due to respiratory complications, clinical phenotypes. Correlations of RCDP3 and bs2 phenotypes, detailed overview |
739078 |
| 2.5.1.26 | malfunction |
silencing of AGPS leads to reduced cellular level of lysophosphatidic acid, lysophosphatidic acid-ether and prostaglandin E2, which can fuel aggressive and progress of cancer. Effect of AGPS on adhesion, invasion and cell cycle of glioma and hepatic carcinoma cells, overview |
739210 |
